Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 1
1983 1
1993 1
2000 1
2002 1
2003 1
2004 1
2005 1
2006 3
2007 2
2008 6
2009 7
2010 5
2011 4
2012 13
2013 8
2014 4
2015 14
2016 12
2017 11
2018 10
2019 18
2020 20
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 22716160

129 results
Results by year
Filters applied: . Clear all
Page 1
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS. Zuardi AW, et al. Curr Pharm Des. 2012;18(32):5131-40. doi: 10.2174/138161212802884681. Curr Pharm Des. 2012. PMID: 22716160 Review.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Zuardi AW, et al. Braz J Med Biol Res. 2006 Apr;39(4):421-9. doi: 10.1590/s0100-879x2006000400001. Epub 2006 Apr 3. Braz J Med Biol Res. 2006. PMID: 16612464 Free article. Review.
A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA, Bossong MG. Iseger TA, et al. Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Schizophr Res. 2015. PMID: 25667194 Review.
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P, Vollenweider FX, Kawohl W. Roser P, et al. World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19. doi: 10.3109/15622970801908047. World J Biol Psychiatry. 2010. PMID: 20218784 Review.
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV, Llorente R, Del Bel EA, Viveros MP, López-Gallardo M, Guimarães FS. Gomes FV, et al. Schizophr Res. 2015 May;164(1-3):155-63. doi: 10.1016/j.schres.2015.01.015. Epub 2015 Feb 10. Schizophr Res. 2015. PMID: 25680767
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Bhattacharyya S, et al. Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18. Neuropsychopharmacology. 2010. PMID: 19924114 Free PMC article. Clinical Trial.
Cannabidiol as a potential treatment for psychosis.
Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Schubart CD, et al. Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15. Eur Neuropsychopharmacol. 2014. PMID: 24309088 Review.
Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
Crippa JA, Hallak JE, Abílio VC, de Lacerda AL, Zuardi AW. Crippa JA, et al. CNS Neurol Disord Drug Targets. 2015;14(8):970-8. doi: 10.2174/1871527314666150909113930. CNS Neurol Disord Drug Targets. 2015. PMID: 26350340 Review.
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S. Deiana S. Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. Epub 2012 Oct 25. Drug Test Anal. 2013. PMID: 23109356
129 results
Jump to page
Feedback